시장보고서
상품코드
1147375

순환종양세포 시장 : 세계 기회 분석 및 산업 예측(2020-2030년)

Circulating Tumor Cell Market: Global Opportunity Analysis and Industry Forecast, 2020-2030 Market

발행일: | 리서치사: Allied Market Research | 페이지 정보: 영문 | 배송안내 : 2-3일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

순환종양세포는 진단전, 치료전, 치료중, 치료후 등 다양한 장면에서 이용될 가능성이 있어, 순환종양세포(CTC) 농축·분리 제품 개발에 종사하는 기업에 유리한 성장 기회를 제공하고 있습니다.

목차

제1장 서론

제2장 주요 요약

제3장 시장 상황

  • 시장 정의와 범위
  • 주요 조사 결과
    • 주요 투자처
    • 주요 성공 전략
  • Porter's Five Forces 분석
    • 공급 기업의 협상력
    • 신규 참여업체의 위협
    • 대체품의 위협
    • 경쟁 기업간 경쟁 관계
    • 구매자의 협상력
  • 시장 점유율 분석/상위 기업 포지셔닝
    • 2021년 시장 점유율 분석/상위 기업 포지셔닝
  • 시장 역학
    • 성장 촉진요인
    • 성장 억제요인
    • 기회
  • COVID-19 영향 분석

제4장 순환종양세포 시장 : 기술별

  • 시장 개요
    • 시장 규모와 예측 : 기술별
  • CTC 검출 강화법
    • 주요 시장 동향, 성장 촉진요인, 기회
    • 시장 규모와 예측 : 지역별
    • 시장 점유율 분석 : 국가별
  • CTC 직접 검출법
    • 주요 시장 동향, 성장 촉진요인, 기회
    • 시장 규모와 예측 : 지역별
    • 시장 점유율 분석 : 국가별
  • CTC 분석
    • 주요 시장 동향, 성장 촉진요인, 기회
    • 시장 규모와 예측 : 지역별
    • 시장 점유율 분석 : 국가별

제5장 순환종양세포 시장 : 응용 분야별

  • 시장 개요
    • 시장 규모와 예측 : 용도별
  • 임상/액체생검
    • 주요 시장 동향, 성장 촉진요인, 기회
    • 시장 규모와 예측 : 지역별
    • 시장 점유율 분석 : 국가별
    • 위험 평가
      • 시장 규모 및 예측
    • 스크리닝과 모니터링
      • 시장 규모와 예측
  • 조사
    • 주요 시장 동향, 성장 촉진요인, 기회 등
    • 시장 규모와 예측 : 지역별
    • 시장 점유율 분석 : 국가별
    • 암 줄기세포 종양형성 연구
      • 시장 규모와 예측
    • 의약품/치료법 개발
      • 시장 규모와 예측

제6장 순환종양세포 시장 : 최종사용자별

  • 시장 개요
    • 시장 규모와 예측 : 최종사용자별
  • 병원 클리닉
    • 주요 시장 동향, 성장 촉진요인, 기회
    • 시장 규모와 예측 : 지역별
    • 시장 점유율 분석 : 국가별
  • 연구학술기관
    • 주요 시장 동향, 성장 촉진요인, 기회
    • 시장 규모와 예측 : 지역별
    • 시장 점유율 분석 : 국가별
  • 진단 센터
    • 주요 시장 동향, 성장 촉진요인, 기회
    • 시장 규모와 예측 : 지역별
    • 시장 점유율 분석 : 국가별

제7장 순환종양세포 시장 : 지역별

  • 시장 개요
    • 시장 규모와 예측 : 지역별
  • 북미
    • 주요 시장 동향과 기회
    • 시장 규모와 예측 : 기술별
    • 시장 규모와 예측 : 용도별
    • 시장 규모와 예측 : 최종사용자별
    • 시장 규모와 예측 : 국가별
    • 미국의 순환종양세포 시장
      • 시장 규모 및 예측 : 기술별
      • 시장 규모 및 예측 : 용도별
      • 시장 규모 및 예측 : 최종사용자별
    • 캐나다의 순환종양세포 시장
      • 시장 규모 및 예측 : 기술별
      • 시장 규모 및 예측 : 용도별
      • 시장 규모 및 예측 : 최종사용자별
    • 멕시코의 순환종양세포 시장
      • 시장 규모 및 예측 : 기술별
      • 시장 규모 및 예측 : 용도별
      • 시장 규모 및 예측 : 최종사용자별
  • 유럽
    • 주요 시장 동향과 기회
    • 시장 규모와 예측 : 기술별
    • 시장 규모와 예측 : 용도별
    • 시장 규모와 예측 : 최종사용자별
    • 시장 규모와 예측 : 국가별
    • 프랑스의 순환종양세포 시장
      • 시장 규모 및 예측 : 기술별
      • 시장 규모 및 예측 : 용도별
      • 시장 규모 및 예측 : 최종사용자별
    • 독일의 순환종양세포 시장
      • 시장 규모 및 예측 : 기술별
      • 시장 규모 및 예측 : 용도별
      • 시장 규모 및 예측 : 최종사용자별
    • 이탈리아의 순환종양세포 시장
      • 시장 규모 및 예측 : 기술별
      • 시장 규모 및 예측 : 용도별
      • 시장 규모 및 예측 : 최종사용자별
    • 스페인의 순환종양세포 시장
      • 시장 규모 및 예측 : 기술별
      • 시장 규모 및 예측 : 용도별
      • 시장 규모 및 예측 : 최종사용자별
    • 영국의 순환종양세포 시장
      • 시장 규모 및 예측 : 기술별
      • 시장 규모 및 예측 : 용도별
      • 시장 규모 및 예측 : 최종사용자별
    • 기타 유럽의 순환종양세포 시장
      • 시장 규모 및 예측 : 기술별
      • 시장 규모 및 예측 : 용도별
      • 시장 규모 및 예측 : 최종사용자별
  • 아시아태평양
    • 주요 시장 동향과 기회
    • 아시아태평양의 시장 규모와 예측 : 기술별
    • 아시아태평양의 시장 규모와 예측 : 용도별
    • 아시아태평양의 시장 규모와 예측 : 최종사용자별
    • 시장 규모와 예측 : 국가별
    • 중국의 순환종양세포 시장
      • 시장 규모 및 예측 : 기술별
      • 시장 규모 및 예측 : 용도별
      • 시장 규모 및 예측 : 최종사용자별
    • 일본의 순환종양세포 시장
      • 시장 규모 및 예측 : 기술별
      • 시장 규모 및 예측 : 용도별
      • 시장 규모 및 예측 : 최종사용자별
    • 인도의 순환종양세포 시장
      • 시장 규모 및 예측 : 기술별
      • 시장 규모 및 예측 : 용도별
      • 시장 규모 및 예측 : 최종사용자별
    • 한국의 순환종양세포 시장
      • 시장 규모 및 예측 : 기술별
      • 시장 규모 및 예측 : 용도별
      • 시장 규모 및 예측 : 최종사용자별
    • 호주의 순환종양세포 시장
      • 시장 규모 및 예측 : 기술별
      • 시장 규모 및 예측 : 용도별
      • 시장 규모 및 예측 : 최종사용자별
    • 기타 아시아태평양의 순환종양세포 시장
      • 시장 규모 및 예측 : 기술별
      • 시장 규모 및 예측 : 용도별
      • 시장 규모 및 예측 : 최종사용자별
  • LAMEA
    • 주요 시장 동향과 기회
    • 시장 규모와 예측 : 기술별
    • 시장 규모와 예측 : 용도별
    • 시장 규모와 예측 : 최종사용자별
    • 시장 규모와 예측 : 국가별
    • 브라질의 순환종양세포 시장
      • 시장 규모 및 예측 : 기술별
      • 시장 규모 및 예측 : 용도별
      • 시장 규모 및 예측 : 최종사용자별
    • 남아프리카공화국의 순환종양세포 시장
      • 시장 규모 및 예측 : 기술별
      • 시장 규모 및 예측 : 용도별
      • 시장 규모 및 예측 : 최종사용자별
    • 사우디아라비아의 순환종양세포 시장
      • 시장 규모 및 예측 : 기술별
      • 시장 규모 및 예측 : 용도별
      • 시장 규모 및 예측 : 최종사용자별
    • UAE의 순환종양세포 시장
      • 시장 규모 및 예측 : 기술별
      • 시장 규모 및 예측 : 용도별
      • 시장 규모 및 예측 : 최종사용자별
    • 기타 LAMEA의 순환종양세포 시장
      • 시장 규모 및 예측 : 기술별
      • 시장 규모 및 예측 : 용도별
      • 시장 규모 및 예측 : 최종사용자별

제8장 기업 개요

  • Ikonisys Inc.
  • Greiner Bio-One International GmbH
  • Thermo Fisher Scientific
  • SRI International
  • STEMCELL Technologies
  • Miltenyi Biotec
  • Menarini Silicon Biosystems
  • QIAGEN Hannover(QIAGEN)
  • F. Hoffmann-La Roche Ltd.
  • NanoString Technologies, Inc
KSM 22.11.17

Circulating tumor cell testing enables the detection and quantification of tumor cells in the blood of cancer patients. Different biological phenotypes of CTCs exist: epithelial, mesenchymal, stem cell-like or mixed. They are present in blood in very small quantities, vastly outnumbered by other cells, especially white blood cells. As a result, their detection needs a phase of isolation-enrichment and a second phase of detection. All the recent CTC identification devices combine these two steps (isolation-enrichment and detection) such as ISET, CellSearch System, CTC-chip or EPISPOT. Sometimes, different methods are used in the same device for one step: for instance, the RosetteSep device includes 2 methods of enrichment/isolation: by density and by immunologic separation which is a negative selection. A number of potential applications of circulating tumor cells in prediagnosis, pre-treatment, and intra and post-treatment provide lucrative growth opportunities to players involved in the development of circulating tumor cell (CTC) enrichment and isolation products.

Covid-19 Scenario analysis:

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the circulating tumour cell market

Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact analysis:

Increased demand for efficient diagnostic and screening tests and technological advancements in cancer detection is expected to propel the growth of market for CTCs. Several tumor markers that have been introduced in recent years can be used with companion diagnostics to monitor or diagnose a variety of cancers. High adoption of companion diagnostics in monitoring tumor eradication characteristics of cytotoxic drugs is among the few factors propelling the demand in the market for CTCs. Key stakeholders are constantly engaged in endeavours aimed at developing circulating tumor cells based tests, which can prove helpful in the cancer diagnosis. The circulating tumor cell testing is also a useful tool for the development of preventive medicine for cancer. Circulating tumor cell testing can help understand and asses the mechanism of drug during in-vitro experiment in preclinical studies.

Drivers:

Increase in preference for minimum invasive procedure:

Growing demand for minimally invasive diagnostic procedures is anticipated to propel investments by key stakeholders in this area. Circulating tumor cell based liquid biopsy tests lead to limited trauma and enable rapid recovery owing to their non-invasive nature. Moreover, it enables minimal invasive screening of tumors before opting for complex surgical procedures, such as radiotherapy, chemotherapy, and surgical removal of tumors, thus positively impacting the adoption.

Increase in prevalence rate of cancer:

The growing prevalence of cancer is one of the major reasons behind the growth of circulating tumor cell testing market. According to NIH, National Cancer Institute, cancer is one of the major reasons of death globally. According to an estimation from the National Cancer Institute, in 2018 colorectal cancer is projected to contribute around 8.1% of all new cancer cases with estimated deaths around 50,630, which is 8.3% of all cancer deaths caused in the U.S.As reported by the Cancer Research UK, there were 41,804 new cases of colorectal cancer in 2015 and 16,384 deaths due to colon cancer in the U.K. Increase in genetic disorder, alcohol consumption, smoking and lifestyle changes are the major factor behind the rise in cancer cases and also contributing factor for the growth of the circulating tumor cell market.

Key Market players:

  • In March 2018, Biocept Inc received a patent for its Target Selector assays for molecular analysis to improve the patient diagnosis with cancer in China.
  • In May 2021, Natera, a company involved in non-invasive genetic testing and the analysis of circulating cell-free DNA, to present successful results of Signatera, to monitor colorectal cancer and identify disease recurrence.

Key benefits of the report:

  • This study presents the analytical depiction of the global circulating tumor cell industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global circulating tumor cell market share.
  • The current market is quantitatively analyzed from 2021 to 2030 to highlight the global circulating tumor cell market growth scenario.
  • Porter's five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed global circulating tumor cell market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions answered in the Circulating tumor cell Market research report:

  • What are the leading market players active in the circulating tumor cell market?
  • What the current trends will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities in the market?
  • What are the projections for the future that would help in taking further strategic steps?

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Share Analysis/Top Player Positioning
    • 3.4.1. Market Share Analysis/Top Player Positioning 2021
  • 3.5. Market Dynamics
    • 3.5.1. Drivers
    • 3.5.2. Restraints
    • 3.5.3. Opportunities
  • 3.6. COVID-19 Impact Analysis

CHAPTER 4: CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY

  • 4.1. Market Overview
    • 4.1.1. Market Size and Forecast, By Technology
  • 4.2. CTC Detection Enrichment Method
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. CTC Direct Detection Methods
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. CTC Analysis
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country

CHAPTER 5: CIRCULATING TUMOR CELL MARKET, BY APPLICATION

  • 5.1. Market Overview
    • 5.1.1. Market Size and Forecast, By Application
  • 5.2. Clinical/Liquid Biopsy
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
    • 5.2.4. Risk Assessment
      • 5.2.4.1. Market Size and Forecast
    • 5.2.4. Screening and Monitoring
      • 5.2.4.1. Market Size and Forecast
  • 5.3. Research
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
    • 5.3.4. Cancer Stem Cell Tumorigenesis Research
      • 5.3.4.1. Market Size and Forecast
    • 5.3.4. Drug/Therapy Development
      • 5.3.4.1. Market Size and Forecast

CHAPTER 6: CIRCULATING TUMOR CELL MARKET, BY END USERS

  • 6.1. Market Overview
    • 6.1.1. Market Size and Forecast, By End Users
  • 6.2. Hospital Clinics
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Research Academic Institutes
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Diagnostic Centres
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country

CHAPTER 7: CIRCULATING TUMOR CELL MARKET, BY REGION

  • 7.1. Market Overview
    • 7.1.1. Market Size and Forecast, By Region
  • 7.2. North America
    • 7.2.1. Key Market Trends and Opportunities
    • 7.2.2. Market Size and Forecast, By Technology
    • 7.2.3. Market Size and Forecast, By Application
    • 7.2.4. Market Size and Forecast, By End Users
    • 7.2.5. Market Size and Forecast, By Country
    • 7.2.6. U.S. Circulating Tumor Cell Market
      • 7.2.6.1. Market Size and Forecast, By Technology
      • 7.2.6.2. Market Size and Forecast, By Application
      • 7.2.6.3. Market Size and Forecast, By End Users
    • 7.2.7. Canada Circulating Tumor Cell Market
      • 7.2.7.1. Market Size and Forecast, By Technology
      • 7.2.7.2. Market Size and Forecast, By Application
      • 7.2.7.3. Market Size and Forecast, By End Users
    • 7.2.8. Mexico Circulating Tumor Cell Market
      • 7.2.8.1. Market Size and Forecast, By Technology
      • 7.2.8.2. Market Size and Forecast, By Application
      • 7.2.8.3. Market Size and Forecast, By End Users
  • 7.3. Europe
    • 7.3.1. Key Market Trends and Opportunities
    • 7.3.2. Market Size and Forecast, By Technology
    • 7.3.3. Market Size and Forecast, By Application
    • 7.3.4. Market Size and Forecast, By End Users
    • 7.3.5. Market Size and Forecast, By Country
    • 7.3.6. France Circulating Tumor Cell Market
      • 7.3.6.1. Market Size and Forecast, By Technology
      • 7.3.6.2. Market Size and Forecast, By Application
      • 7.3.6.3. Market Size and Forecast, By End Users
    • 7.3.7. Germany Circulating Tumor Cell Market
      • 7.3.7.1. Market Size and Forecast, By Technology
      • 7.3.7.2. Market Size and Forecast, By Application
      • 7.3.7.3. Market Size and Forecast, By End Users
    • 7.3.8. Italy Circulating Tumor Cell Market
      • 7.3.8.1. Market Size and Forecast, By Technology
      • 7.3.8.2. Market Size and Forecast, By Application
      • 7.3.8.3. Market Size and Forecast, By End Users
    • 7.3.9. Spain Circulating Tumor Cell Market
      • 7.3.9.1. Market Size and Forecast, By Technology
      • 7.3.9.2. Market Size and Forecast, By Application
      • 7.3.9.3. Market Size and Forecast, By End Users
    • 7.3.10. UK Circulating Tumor Cell Market
      • 7.3.10.1. Market Size and Forecast, By Technology
      • 7.3.10.2. Market Size and Forecast, By Application
      • 7.3.10.3. Market Size and Forecast, By End Users
    • 7.3.11. Rest Of Europe Circulating Tumor Cell Market
      • 7.3.11.1. Market Size and Forecast, By Technology
      • 7.3.11.2. Market Size and Forecast, By Application
      • 7.3.11.3. Market Size and Forecast, By End Users
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends and Opportunities
    • 7.4.2. Market Size and Forecast, By Technology
    • 7.4.3. Market Size and Forecast, By Application
    • 7.4.4. Market Size and Forecast, By End Users
    • 7.4.5. Market Size and Forecast, By Country
    • 7.4.6. China Circulating Tumor Cell Market
      • 7.4.6.1. Market Size and Forecast, By Technology
      • 7.4.6.2. Market Size and Forecast, By Application
      • 7.4.6.3. Market Size and Forecast, By End Users
    • 7.4.7. Japan Circulating Tumor Cell Market
      • 7.4.7.1. Market Size and Forecast, By Technology
      • 7.4.7.2. Market Size and Forecast, By Application
      • 7.4.7.3. Market Size and Forecast, By End Users
    • 7.4.8. India Circulating Tumor Cell Market
      • 7.4.8.1. Market Size and Forecast, By Technology
      • 7.4.8.2. Market Size and Forecast, By Application
      • 7.4.8.3. Market Size and Forecast, By End Users
    • 7.4.9. South Korea Circulating Tumor Cell Market
      • 7.4.9.1. Market Size and Forecast, By Technology
      • 7.4.9.2. Market Size and Forecast, By Application
      • 7.4.9.3. Market Size and Forecast, By End Users
    • 7.4.10. Australia Circulating Tumor Cell Market
      • 7.4.10.1. Market Size and Forecast, By Technology
      • 7.4.10.2. Market Size and Forecast, By Application
      • 7.4.10.3. Market Size and Forecast, By End Users
    • 7.4.11. Rest of Asia Pacific Circulating Tumor Cell Market
      • 7.4.11.1. Market Size and Forecast, By Technology
      • 7.4.11.2. Market Size and Forecast, By Application
      • 7.4.11.3. Market Size and Forecast, By End Users
  • 7.5. LAMEA
    • 7.5.1. Key Market Trends and Opportunities
    • 7.5.2. Market Size and Forecast, By Technology
    • 7.5.3. Market Size and Forecast, By Application
    • 7.5.4. Market Size and Forecast, By End Users
    • 7.5.5. Market Size and Forecast, By Country
    • 7.5.6. Brazil Circulating Tumor Cell Market
      • 7.5.6.1. Market Size and Forecast, By Technology
      • 7.5.6.2. Market Size and Forecast, By Application
      • 7.5.6.3. Market Size and Forecast, By End Users
    • 7.5.7. South Africa Circulating Tumor Cell Market
      • 7.5.7.1. Market Size and Forecast, By Technology
      • 7.5.7.2. Market Size and Forecast, By Application
      • 7.5.7.3. Market Size and Forecast, By End Users
    • 7.5.8. Saudi Arabia Circulating Tumor Cell Market
      • 7.5.8.1. Market Size and Forecast, By Technology
      • 7.5.8.2. Market Size and Forecast, By Application
      • 7.5.8.3. Market Size and Forecast, By End Users
    • 7.5.9. UAE Circulating Tumor Cell Market
      • 7.5.9.1. Market Size and Forecast, By Technology
      • 7.5.9.2. Market Size and Forecast, By Application
      • 7.5.9.3. Market Size and Forecast, By End Users
    • 7.5.10. Rest of LAMEA Circulating Tumor Cell Market
      • 7.5.10.1. Market Size and Forecast, By Technology
      • 7.5.10.2. Market Size and Forecast, By Application
      • 7.5.10.3. Market Size and Forecast, By End Users

CHAPTER 8: COMPANY PROFILES

  • 8.1. Ikonisys Inc.
    • 8.1.1. Company Overview
    • 8.1.2. Key Executives
    • 8.1.3. Company Snapshot
    • 8.1.4. Operating Business Segments
    • 8.1.5. Product Portfolio
    • 8.1.6. Business Performance
    • 8.1.7. Key Strategic Moves and Developments
  • 8.2. Greiner Bio-One International GmbH
    • 8.2.1. Company Overview
    • 8.2.2. Key Executives
    • 8.2.3. Company Snapshot
    • 8.2.4. Operating Business Segments
    • 8.2.5. Product Portfolio
    • 8.2.6. Business Performance
    • 8.2.7. Key Strategic Moves and Developments
  • 8.3. Thermo Fisher Scientific
    • 8.3.1. Company Overview
    • 8.3.2. Key Executives
    • 8.3.3. Company Snapshot
    • 8.3.4. Operating Business Segments
    • 8.3.5. Product Portfolio
    • 8.3.6. Business Performance
    • 8.3.7. Key Strategic Moves and Developments
  • 8.4. SRI International
    • 8.4.1. Company Overview
    • 8.4.2. Key Executives
    • 8.4.3. Company Snapshot
    • 8.4.4. Operating Business Segments
    • 8.4.5. Product Portfolio
    • 8.4.6. Business Performance
    • 8.4.7. Key Strategic Moves and Developments
  • 8.5. STEMCELL Technologies
    • 8.5.1. Company Overview
    • 8.5.2. Key Executives
    • 8.5.3. Company Snapshot
    • 8.5.4. Operating Business Segments
    • 8.5.5. Product Portfolio
    • 8.5.6. Business Performance
    • 8.5.7. Key Strategic Moves and Developments
  • 8.6. Miltenyi Biotec
    • 8.6.1. Company Overview
    • 8.6.2. Key Executives
    • 8.6.3. Company Snapshot
    • 8.6.4. Operating Business Segments
    • 8.6.5. Product Portfolio
    • 8.6.6. Business Performance
    • 8.6.7. Key Strategic Moves and Developments
  • 8.7. Menarini Silicon Biosystems
    • 8.7.1. Company Overview
    • 8.7.2. Key Executives
    • 8.7.3. Company Snapshot
    • 8.7.4. Operating Business Segments
    • 8.7.5. Product Portfolio
    • 8.7.6. Business Performance
    • 8.7.7. Key Strategic Moves and Developments
  • 8.8. QIAGEN Hannover (QIAGEN)
    • 8.8.1. Company Overview
    • 8.8.2. Key Executives
    • 8.8.3. Company Snapshot
    • 8.8.4. Operating Business Segments
    • 8.8.5. Product Portfolio
    • 8.8.6. Business Performance
    • 8.8.7. Key Strategic Moves and Developments
  • 8.9. F. Hoffmann-La Roche Ltd.
    • 8.9.1. Company Overview
    • 8.9.2. Key Executives
    • 8.9.3. Company Snapshot
    • 8.9.4. Operating Business Segments
    • 8.9.5. Product Portfolio
    • 8.9.6. Business Performance
    • 8.9.7. Key Strategic Moves and Developments
  • 8.10. NanoString Technologies, Inc
    • 8.10.1. Company Overview
    • 8.10.2. Key Executives
    • 8.10.3. Company Snapshot
    • 8.10.4. Operating Business Segments
    • 8.10.5. Product Portfolio
    • 8.10.6. Business Performance
    • 8.10.7. Key Strategic Moves and Development
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제